Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 8910 results

  1. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Awaiting development Reference number: GID-TA11851 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

    Health technology evaluations
    In development

  3. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. AHEAD implants for external ear prosthesis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  10. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  11. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  14. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development